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Background: TGFβ signaling has typically been associated with suppression of tumor initiation while the role it
plays in metastasis is generally associated with progression of malignancy. However, we present evidence here for
an anti-metastatic role of TGFβ signaling.
Methods: To test the importance of TGFβ signaling to cell survival and metastasis we compared human colon
carcinoma cell lines that are either non-tumorigenic with TGFβ response (FET), or tumorigenic with TGFβ response
(FETα) or tumorigenic with abrogated TGFβ response via introduction of dominant negative TGFβRII (FETα/DN) and
their ability to metastasize. Metastatic competency was assessed by orthotopic transplantation. Metastatic colony
formation was assessed histologically and by imaging.
Results: Abrogation of TGFβ signaling through introduction of a dominant negative TGFβ receptor II (TGFβRII) in
non-metastatic FETα human colon cancer cells permits metastasis to distal organs, but importantly does not reduce
invasive behavior at the primary site. Loss of TGFβ signaling in FETα-DN cells generated enhanced cell survival
capabilities in response to cellular stress in vitro. We show that enhanced cellular survival is associated with
increased AKT phosphorylation and cytoplasmic expression of inhibitor of apoptosis (IAP) family members (survivin
and XIAP) that elicit a cytoprotective effect through inhibition of caspases in response to stress. To confirm that
TGFβ signaling is a metastasis suppressor, we rescued TGFβ signaling in CBS metastatic colon cancer cells that had
lost TGFβ receptor expression due to epigenetic repression. Restoration of TGFβ signaling resulted in the inhibition
of metastatic colony formation in distal organs by these cells. These results indicate that TGFβ signaling has an
important role in the suppression of metastatic potential in tumors that have already progressed to the stage of an
invasive carcinoma.
Conclusions: The observations presented here indicate a metastasis suppressor role for TGFβ signaling in human
colon cancer cells. This raises the concern that therapies targeting inhibition of TGFβ signaling may be imprudent
in some patient populations with residual TGFβ tumor suppressor activity.Background
Metastatic disease accounts for 90% of cancer related
deaths in all cancers [1]. The metastatic process requires
the ability of the tumor to invade at the primary site,
undergo intravasation, survive immune surveillance in
blood circulation, undergo extravasation at a distal organ* Correspondence: mbrattain@unmc.edu
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[2]. Molecular mechanisms involved in the establishment
of metastases are largely unknown. Understanding mo-
lecular mechanisms involved in the metastatic process
could identify novel potential targets for development of
more effective therapeutic intervention against established
metastatic disease.
An important aspect of metastatic potential is the abil-
ity of a cancer cell to evade apoptotic signals under
stress conditions which could normally lead to cell death
[3,4]. Evasion of apoptosis can occur as a result of lossLtd; licensee BioMed Central Ltd. This is an Open Access article distributed under
n License (http://creativecommons.org/licenses/by/2.0), which permits
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activity thus shifting the balance of stress response to-
ward inappropriate cell survival. Many cellular pathways
have been linked to enhanced survival or anti-apoptotic
signaling and malignant progression; here we investi-
gated the role of transforming growth factor-β (TGFβ)
in an orthotopic colorectal cancer model of metastasis.
The general consensus is that TGFβ signaling is tumor
suppressive in early carcinogenesis, but it becomes
tumor promoting during later stages of cancer [5]. TGFβ
signaling through Smad activation is regarded as tumor
suppressive during the early stages of cancer and pre-
cancerous lesions as it has been shown that loss of TGFβ
tumor suppressor signaling has been associated with
tumor initiation and progression of several types of
tumors including colon cancer. TGFβRII has been
shown to be inactivated by mutation in human colon
cancers with microsatellite instability [6]. Other types of
cancer as well as some subsets of colon cancer are often
associated with epigenetic transcriptional repression of
TGFβ receptors rather than mutational inactivation of
the pathway [7-9], ultimately contributing to a loss in
growth control as well as resistance to apoptosis [10,11].
Studies conducted in breast cancer demonstrated that
the unmodified transcription factor Sp3 induces tran-
scriptional repression of TGFβRII promoter [7]; conse-
quently, treatment with histone deacetylase inhibitor,
Trichostatin A (TSA), results in acetylated Sp3 which
alleviates transcriptional repression of TGFβRII gene ex-
pression [8]. On the other hand, it has been reported
that increased expression of receptor ligands by tumor
cells was associated with tumor progression in non-
small cell lung cancer (NSCLC), colorectal cancer and
gastric carcinomas [12-14]. Thus, one view is that TGFβ
tumor promotion may occur predominantly in situations
where signaling receptor expression is deficient [15].
Loss of TGFβ tumor suppressor signaling is important
in a tumor cell’s ability to evade apoptotic signaling in
the tumor microenvironment. Previously, our laboratory
identified the linkage of TGFβ tumor suppressor activity
to the repression of pro-survival PI3K/AKT signaling
and linked the PI3K/AKT pathway to survivin expres-
sion in human colon carcinoma cell lines [16]. AKT has
a wide variety of substrates involved in many cellular
responses including proliferation, apoptosis and growth.
Over-expression and/or constitutive signaling of PI3K/
AKT pathway components have frequently been impli-
cated in the regulation of cell survival and their associ-
ation with tumor progression [17].
Survivin, also known as Birc5, is a 16.5 kDa protein
that is the smallest member of the inhibitors of apop-
tosis (IAP) family. Survivin is expressed in the nucleus,
the cytosol and the mitochondria. Survivin is expressed
in proliferating cells such as embryonic and fetal cellsand is undetectable in differentiated normal tissue; how-
ever, survivin is highly expressed in numerous solid
tumor types including colon, breast, lung and liver, and
its expression is associated with aberrant cell survival
and tumor progression [18-20]. Overexpression of survi-
vin has been associated with inhibition of cell death
initiated by extrinsic or intrinsic apoptotic pathways
[21]. Survivin expression is associated with poor clinical
prognosis in many tumor types including colon, lung
and breast [22-25]. Survivin protects X-linked inhibitor
of apoptosis (XIAP) from proteasomal degradation and
antagonizes apoptosome-mediated cell death through
the ability of XIAP to inhibit caspase activation [26]. It
has been shown that upon cellular stress, mitochondrial
survivin is released into the cytosol where it interacts
and stabilizes XIAP and provides protection from cell
death [27]. The Bir2 domain of XIAP has been linked
with inhibition of caspase 3 and caspase 7; and the Bir3
domain with caspase 9 inhibition [28]. AKT/PKB-
mediated phosphorylation of XIAP within the Bir1 do-
main is implicated in reducing auto-ubiquitination and
enhanced protein stabilization [29].
Many studies indicate that aberrant TGFα/EGFR sig-
naling is involved in tumor progression [30-34]. The
FET colon cancer cell line which normally does not form
subcutaneous xenografts in athymic mice [35] becomes
highly tumorigenic after TGFα (transforming growth
factor-α) transfection to generate constitutive EGFR
(epidermal growth factor receptor) activation [36]. FET
cells have robust autocrine TGFβ signaling that inhibits
cell proliferation and contributes to apoptosis in re-
sponse to stress [16]. We show here that FETα cells ex-
hibit robust invasion at the primary site after orthotopic
implantation. The ability to invade at the primary site is
the key attribute in the assignment of cancer diagnosis
[37]. Importantly, however, despite invasive capabilities,
the FETα cells rarely metastasize when implanted at the
orthotopic site of the colon in athymic mice. Ye et al.
[38] demonstrated that repression of TGFβ activity by
transfection of dominant negative (DN) TGFβRII was
sufficient to lead to vigorous tumor growth by FET cells
in subcutaneous implants; however, as with FETα cell
induced tumors FETDNRII orthotopic implants without
ectopic TGFα expression resulted in invasive primary
cancers that rarely metastasized. Since the TGFβ recep-
tor/SMAD signaling in FETα cells remained intact, we
hypothesized that suppression of this pathway would be
sufficient to generate a metastatic phenotype in associ-
ation with increased resistance to apoptosis in response
to stress from orthotopic transplants. Two mechanisms
contributing to increased survival associated with loss of
TGFβ tumor suppressor activity are constitutive AKT
activation and survivin/XIAP expression. These results
show that in addition to suppression of tumor initiation,
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suppression in established carcinomas. To substantiate our
findings that TGFβ signaling is a metastatic suppressor in
established carcinomas, we utilized a human colon carcin-
oma cell line (designated CBS) that is metastatic after
orthotopic implantation and demonstrates loss of TGFβ
signaling due to epigenetic repression of the TGFβRII.
Ectopic expression of TGFβRII in CBS-RII cells resulted in
primary carcinoma formation as reflected by invasion, but
was accompanied by suppression of the metastatic pheno-
type in the orthotopic implantation model. Also, reintro-
duction of Smad-dependent TGFβ signaling resulted in
decreased expression of cytoplasmic survivin and XIAP in
CBS-RII cells. Taken together, our results suggest that res-
toration of TGFβ signaling in non-responsive metastatic
cells can inhibit cell survival and metastases. Moreover, the
role of TGFβ receptor/Smad signaling in curtailing meta-
static progression in primary invasive carcinoma suggests
that strategies involving inhibition of TGFβ signaling for
cancer treatment may be ill-advised for some subpopula-
tions of cancer patients.
Methods
Cell lines and reagents
FETα and FETα-DN colon carcinoma cells were cultured
at 37°C in a humidified atmosphere of 5% CO2 in SM
medium [McCoy’s 5A serum-free medium (Sigma) with
pyruvate, vitamins, amino acids, and antibiotics] supple-
mented with 10 ng/mL EGF, 20 μg/mL insulin, and
4 μg/mL transferrin. When the cells were subjected to
growth factor deprivation stress (GFDS), they were cultured
in SM medium in the absence of growth factor or serum
supplements for 24 or 48 h without medium changes in be-
tween. Antibodies for poly (ADP-ribose) polymerase
(PARP), AKT, phosphorylated AKT (Ser473), and survivin
were obtained from Cell Signaling Technology. Actin and
tubulin antibodies were purchased from Sigma. P-Smad2
and XIAP antibodies were from Chemicon and Abcam, re-
spectively. PI3K inhibitor LY294002, and TGFβ were
obtained from Calbiochem. Apoptag plus Peroxidase In
Situ Apoptosis Detection kit was from Millipore/Chemicon
and both the DAKO Envision System HRP and the mono-
clonal anti-Human KI-67 antigen (Clone Mib-1) were from
DAKO North America. Annexin V-FITC Apoptosis Detec-
tion kit (including propidium iodide) was from BD Bio-
science Pharmingen while the Cell Death Detection
ELISAPLUS kit was from Roche Diagnostics. Hematoxylin
was obtained from Protocol and eosin was from Sigma-
Aldrich.
Ectopic expression of dominant negative TGFβRII
receptor
The DNRII expression vector was described previously
[38]. The cDNA was subcloned into a MX-IV retroviralvector. The 293GP packaging cells (Clontech, Mountain
View, CA) were co-transfected with pVSV-G. The
viruses were harvested 48 h later and used to infect
FETα cells. Puromycin (3.0 μg/mL) was used to select
infected cells for 8 days and then cells were pooled.
Immunoblot analysis
Cells were lysed in TNESV lysis buffer [50 mmol/L Tris
(pH 7.5), 150 mmol/L NaCl, 1% NP40, 50 mmol/L NaF,
1 mmol/L Na3VO4, 25 μg/mL h-glycerophosphate,
1 mmol/L phenylmethylsulfonyl fluoride, one protease
inhibitor cocktail tablet (Roche, Indianapolis, IN) per
10 mL] for 30 minutes on ice. The supernatants were
then collected by centrifugation at 21,000×g for 15 min-
utes at 4°C. Protein was determined by the Pierce BSA
method. Proteins samples were dissolved in 1× sample
buffer (50 mM Tris, pH6.8, 1% SDS, 10% glycerol, 0.03%
bromophenol blue and 1% β-mercaptoethanol). Protein
(10–50 μg) was fractionated on a 10% acrylamide de-
naturing gel and transferred onto a nitrocellulose mem-
brane (Life Science, Amersham) by electroblotting. The
membrane was blocked with 5% nonfat dry milk in
TBST [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl,
0.05% Tween 20] for 1 h at room temperature or over-
night at 4°C and washed in TBST. The membrane was
then incubated with primary antibodies at 1:1000 dilu-
tions for 1 h at room temperature or overnight at 4°C.
After washing with TBST for 30 min, the membranes
were then incubated with peroxidase-conjugated goat
anti-mouse or anti-rabbit IgG (Jackson ImmunoRe-
search Laboratories, Inc) at a 1:1,000 dilution for 1 h at
room temperature. After further washing in TBST for
30 min, the proteins were detected by the enhanced
chemiluminescence (ECL) system (Amersham) or Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific).
Immunoprecipitation
Cells were lysed in TNESV lysis buffer for 30 minutes on
ice. The supernatants were then collected by centrifuga-
tion at 21,000×g for 15 minutes at 4°C. Protein was deter-
mined by the Pierce BSA method. Protein (300 ug) was
pre-cleared with 10ul of protein A/G beads and lysis buf-
fer for 30 minutes at 4°C. Samples were centrifuged at
21,000 × g at 4°C for 10 minutes followed by collection of
the supernatant. The supernatant was incubated while ro-
tating with antibody (according to the manufacturer’s spe-
cifications) at 4°C for 60 minutes, followed by addition of
25 ul protein A/G beads and tumbled overnight. Samples
were centrifuged at 21,000 × g for 1 minute at 4°C. The
supernatant was collected to probe for actin as an experi-
mental control, while the pellet was washed 3 times for 5
minutes in lysis buffer at 21,000 × g at 4°C, each time the
supernatant was decanted. The pellets were dissolved in
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glycerol, 0.03% bromophenol blue and 1% β-mercap-
toethanol) and boiled for 5 minutes at 95°C, then spun
and loaded on SDS-PAGE gel.
DNA fragmentation (cell death ELISA)
Apoptosis was quantified by a DNA fragmentation
ELISA. Briefly, cells were seeded in plates in serum-free
medium and allowed to attach for 24 hours. Medium was
changed on alternate days until 80% confluence was
attained. Next, the medium was changed to supplemental
McCoys for 24 or 48 h of growth factor deprivation stress
(GFDS). DNA fragmentation was detected by the Cell
Death Detection ELISA Plus kit (Roche, Indianapolis, IN)
according to the manufacturer’s instructions. DNA frag-
mentation was normalized by MTT assays derived at
identical treatment conditions.
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide)
Cells were grown to 80% confluence then MTT was added
to the medium followed by incubation at 37°C for 2 h. The
medium was aspirated to visualize stained cells. DMSO
was added and the plate was covered with foil followed by
shaking for 15 min. Duplicates volumes (150 μL) were
added to a 96-well plate and the absorbance was observed
at 570 nm.
[3H] Thymidine incorporation
[3 H] Thymidine incorporation was used to determine
cell cycle inhibition of FETα and FETαDN cells after
TGF-β treatment. The cells were seeded in six-well tis-
sue culture plates and grown to 60% confluence. At 48 h
after TGFβ treatment, the cells were labeled with [3H]
thymidine (7 μCi; 46 Ci/mmol; Amersham Corp.) for
1 h. DNA was then precipitated with 10% trichloroacetic
acid and solubilized in 0.2 mol/L NaOH. The amount of
[3H] thymidine incorporated was analyzed by liquid
scintillation counting in a Beckman LS7500 scintillation
counter.
Immunohistochemistry (IHC)
Primary tumors established from the FETα and FETα-
DN cells were harvested and placed in 10% neutral
buffered formalin fixative for 12 to 24 hrs and then em-
bedded in paraffin. Deparaffinized tissue specimens were
subjected to immunohistochemical staining for the
detection of pAKT-S473, survivin and XIAP using an in-
direct detection method [39]. The catalyzed signal amp-
lification system was used for the phosphospecific
antibodies (Dako Corporation, Carpinteria, CA). The
antibody staining was accompanied by a negative control
in which slides were incubated with a matching blocking
peptide (Dako Corporation) to the primary antibody.Specimens were processed on the same day to eliminate
any variability in conditions. Slides were digitally photo-
graphed using the same settings.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay
Slides were cut from paraffin embedded blocks and
stained according to the Apotag (Oncor, Gaithersburg,
MD) terminal nucleotidyl transferase–mediated nick end
labeling (TUNEL) assay kit. The apoptotic rate was
quantitatively determined by counting the number of
positively stained apoptotic bodies per 75 μm2 field at
200x magnification. Twelve and fifteen histological slides
for the FETα and FETα-DN tumors, respectively, were
analyzed. Three histologically similar fields viewed at
200X were randomly selected from each slide for ana-
lysis. This procedure was performed by two blinded
observers. The ratio of the average number of apoptotic
cells to the total number of cells counted was used to
represent apoptotic rates.
KI-67 staining
Slides cut from paraffin embedded blocks were also used
for H&E stains and for immunohistochemical characteri-
zations. Serial sections were cut to complement the
H&E sections and were stained with an IgG1 rabbit poly-
clonal antibody for Ki-67 (Dako Corporation). Ki-67 is a
non-histone nuclear antigen present in late G1, G2, and
S phase of the cell cycle but not G0. The optimal dilu-
tion of 1:100 was used. Three- to 4-μm sections were
cut, deparaffinized in xylene, and rehydrated in descend-
ing grades of ethanol. Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide in water.
Immunostaining was done using a variation of the
avidin-biotin-peroxidase method. Slides were counter-
stained with methyl green. The proliferation rate was
determined quantitatively by utilization of NIH Image J
(public domain software). Image settings were as follows:
threshold range 10–192; pixel size 20–5000. Twelve
slides from FETα and FETα-DN were analyzed. Three
histologically similar fields viewed at 200X were ran-
domly selected for analysis. The mean proliferation was
determined for each group.
Subcellular fractionation
Cells were washed with phosphate buffered saline (PBS)
then lysed using 500 μl of fractionation buffer (250 mM
Sucrose, 20 mM HEPES pH7.4, 0 mM KCl, 1.5 mM
MgCl2, 1 mM EDTA, mM EGTA). Cells were scraped
immediately and placed in a 1.5 ml eppendorf tube on
ice. Collected cells were then passed through a 25 G
needle 10 times, and incubated on ice for 20 min. Cells
were centrifuged at 720 × g (360 rpm) for 5 min to iso-
late the nuclear pellet from the supernatant containing
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tionation buffer and passed through a 25 G needle 10
times followed by centrifugation at 720 × g (360 rpm)
for 10 min again. The supernatant containing the cyto-
plasm was centrifuged at 14,000 × g (8000 rpm) for
10 min to yield the cytosolic fraction (supernatant) and
the mitochondrial fraction (the pellet). The mitochon-
drial pellet was washed with fractionation buffer and
passed through a 25 G needle 10 times followed by cen-
trifugation at 14,000 × g (8000 rpm) for 10 min again
then re-suspended in the appropriate volume of fraction-
ation buffer.
Orthotopic implantation
Orthotopic implantation was performed as previously
described [40]. Briefly, green fluorescent protein (GFP)-
labeled FETα and FETα-DN cells (5 × 106) were sub-
cutaneously injected onto the dorsal surfaces of separate
BALB/c nude male mice and allowed to grow to
300 mm3. Once xenografts were established, they were
excised and minced into 1 mm3 pieces. Two of these
pieces were then orthotopically implanted into the colon
of other BALB/c nude mice. Forty four animals were
implanted with FETα xenografts and 30 animals with
FETα-DN xenografts. For operative procedures, animals
were anesthetized with isoflurane inhalation. A 1-cm
laparotomy was performed and the cecum and ascend-
ing colon were exteriorized. Using 7X magnification and
microsurgical techniques, the serosa was disrupted in
two locations. Pieces of xenograft (1 mm3) were subsero-
sally implanted using an 8–0 nylon suture at the dis-
rupted serosal locations. The bowel was then returned
to the peritoneal cavity and the abdomen was closed
with 5–0 vicryl suture. Fluorescence imaging was per-
formed weekly on the animals to follow tumor growth
(LightTools). Animals were euthanized at 7–9 weeks
after implantation. Organs were explanted, imaged, and
immediately placed in buffered 10% formalin. Tissues
were then processed and embedded in paraffin. Histo-
logical slides were cut for H&E staining. Metastases were
determined by histological evaluation of each liver lobe
and both lungs as previously described in detail [41,42].
All animal work was done in accordance with the Insti-
tutional Animal Care and Use Committees (IACUC)
regulations. Protocol number was 920 M.
Imaging
Starting at one week post-implantation, animals were
anesthetized with a 1:1 mixture of ketamine (10 mg/ml)
and xylazine (1 mg/ml) by intraperitoneal injection
(0.01 ml/mg) and weekly GFP fluorescence imaging was
performed for up to seven weeks. Specifically, GFP fluor-
escence imaging was performed using a light box illumi-
nated by fiber optic lighting at 470 nm (Illumatool BLS,Lightools Research, Encinitas, CA) using a Retiga EXi
color CCD camera (QImaging, Burnaby BC, Canada).
High-resolution images consisting of 1,360 X 1036 pixels
were captured directly using a MS-Windows based PC.
Images were visually optimized for contrast and bright-
ness using commercial software (Adobe Photoshop, CS2
Adobe, San Jose, CA). Excitation of GFP in the light box
facilitated identification of primary and metastatic dis-
ease by direct near-real time visualization of fluores-
cence in live animals.
Results
TGFβ suppresses metastasis in vivo
We have reported that the FET cell line which was iso-
lated from a human colon cancer is immortalized and
grows with anchorage independence, but does not form
tumors in athymic mice after subcutaneous implantation
[32]. Stable transfection with a construct coding for ac-
tive (processed) TGFα under TET off control resulted in
progressive growth at the subcutaneous site in the ab-
sence of TET. With the addition of TET the FETα
tumors showed regression in association with high apop-
totic rates as reflected by TUNEL [33]. FETα cells as
well as the parental FET cell line have a high sensitivity
to TGFβ in contrast to most cancer derived cell lines.
We hypothesized that TGFβ signaling suppresses metas-
tasis of FETα cells. To test this hypothesis, we stably co-
transfected FETα cells with a dominant negative RII re-
ceptor construct and denoted these cells as FETα-DN.
Abrogation of TGFβ signaling was confirmed by treating
FETα and FETα-DN cells with varying concentrations of
TGF β [0, 5, 10 ng/mL] for 2 h followed by immunoblot
analysis. Phospho-Smad2 was used as an indicator of
functional TGFβ signaling. FETα cells showed a
concentration-dependent induction of pSmad2 while
FETα-DN cells showed no pSmad2 expression. This re-
sult confirmed loss of TGFβ receptor mediated Smad
signaling in FETα-DN (see Additional file 1).
Comparison of FETα and FETα-DN cells by orthoto-
pic implantation was used to assess the effect of loss of
TGFβ receptor/Smad signaling on malignant progression
beyond the first step of the metastatic process (invasion
of the primary tumor) as reflected by metastatic
colonization of distant organs from the primary tumor
site. Forty four animals were implanted with FETα cells
and 30 animals with FETα-DN cells. Metastatic spread
was analyzed in liver and/or lungs of transplanted mice
as described in the methods. The presence or absence of
metastatic disease was determined by microscopic histo-
logical analysis of lungs and liver from mice bearing
orthotopic implants as previously described [42]. We
observed 100% primary tumor growth and invasion at
the primary site of implantation for all animals, however
only 2/44 animals showed metastatic colony formation
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Figure 1 Orthotopic implantation of xenografts formed by
FETα and FETα-DN cells are shown. (A) Fluorescent images of
isolated primary tumors and lungs from FETα orthotopically
implanted animals. Green fluorescence reflects colony formation.
Note the lack of fluorescent nodules. (B) Fluorescent images of
isolated primary tumors and lungs from FETα-DN orthotopically
implanted animals. Green fluorescence reflects colony formation.
(C) Primary tumors from FETα and FETα-DN orthotopic implants
highlighting the leading edge of invasion (top); and of metastases in
the lungs of orthotopic FETα-DN implanted animals with H&E
staining. Images were captured at 200x magnification.
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FETα cells (Table 1). Figure 1A shows images of FETα
implants with GFP fluorescence of isolated primary
tumor tissue and lungs with no visible GFP fluorescence.
Table 2 summarizes the results of orthotopic implant-
ation with subcutaneous xenografts formed by injection
of FETα-DN cells. As with FETα orthotopic implants we
observed 100% primary tumor growth and invasion at
the primary site of implantation for all animals: in
addition, visible GFP fluorescence from metastatic cells
was evident in the lungs. The results show that 23/30
animals from FETα-DN bearing animals had metastatic
colony formation in the lungs. Figure 1B shows images
of FETα-DN implants with GFP fluorescence by primary
tumor tissue and lungs with visible deposits of GFP
fluorescent colonies. Metastatic colonization was also
evaluated histologically by hematoxylin and eosin (H&E)
staining as described in the methods. Figure 1C shows
H&E staining of FETα and FETα-DN primary tumors;
as well as metastatic colonies in the lungs of FETα-DN
orthotopically implanted animals. These results indicate
that while FETα and FETα-DN cells are both 100% inva-
sive at the primary implanted site, however, there was a
robust increase observed in metastatic potential after re-
moval of TGFβ signaling by DNRII. FETα bearing ani-
mals had a 5% metastatic rate compared to a 77%
metastatic rate observed in FETα-DN bearing animals
for equally sized primary tumors using previously
described histological assessment methodology [42].
The increased metastatic capability of FETα-DN
implants suggests that these cells acquired enhanced
survival capabilities enabling them to escape from the
primary tumor site to form colonies at a distal organ site
as a result of loss of TGFβ inhibitory signaling. Prolifera-
tive potential and survival signaling were assessed in situ
by KI-67 [43] and TUNEL assays [44] as previously
described [42]. Immunohistochemical staining of KI-67
showed that both FETα and FETα-DN tumors had posi-
tive staining for KI-67 antigen. KI-67 staining indicated
no differences in the proliferation rates between FETα
and FETα-DN implanted animals (Figure 2A and 2B).
However, TUNEL staining was higher in tumors from
FETα implanted animals thus, reflecting a larger number
of cells undergoing apoptosis in FETα tumors as com-
pared to FETα-DN tumors (Figure 2C). The apoptotic
rate of FETα implants was 2.5-fold that of FETα-DN
implants (Figure 2D). Taken together these results indi-
cate that the level of TGFβ receptor/Smad signaling in







(5%)and invasion, but does suppress the progression of a pri-
mary invasive carcinoma to a robust metastatic capabil-
ity. Thus, shifting the tumor suppressor/oncogenic balance
toward oncogenesis by constitutive EGFR activation allows
for malignancy, but not a robust metastatic phenotype due
to continued metastasis suppressor signaling by TGFβ.
Abrogation of TGFβ tumor suppressor signaling in vitro
results in enhanced survival during GFDS
The ability of FETα cells to carry out invasion at the pri-
mary site, but not carry out subsequent aspects of the
metastatic cascade due to TGFβ signaling suggests that
this tumor suppressor activity is strong enough to shift
the balance of tumor suppressor/oncogenesis signaling
toward cell death when these cells encounter the stresses

































































Figure 2 Enhanced cell survival capability of FETα-DN cells
results in metastasis. Primary tumors established in animals
orthotopically implanted with FETα and FETα-DN tumors were
processed for (A-B) KI-67 staining and were analyzed to evaluate the
proliferation rate. Primary tumors established in animals
orthotopically implanted with FETα and FETα-DN tumors were
processed for (C-D) TUNEL staining and were analyzed to evaluate
the apoptotic rate. Both KI-67 and TUNEL images were captured at
200x magnification. Image J software was employed to quantify
positive staining cells and the total number of cells. Statistical
significance was determined using two tailed student’s t test with p
value less than 0.05.

























































































































Figure 3 Evidence for enhanced cell survival in vitro. FETα and
FETα-DN cells were grown to 80% confluence followed by growth
factor deprivation for 48 h and probed for differences in apoptosis
as reflected by several approaches. (A) Western blot analysis was
performed for PARP and cleaved PARP antibodies, using actin as a
loading control. (B) DNA fragmentation assay was utilized to
determine apoptosis. Error bars represent S.E. (C) Western blot
analysis was performed for AKT phosphorylation at S473, using total
AKT as the experimental control. (D) DNA fragmentation assay of
LY294002 (25uM) treated FETα cells under GFDS conditions
described in the Material and Methods. Error bars represent S.E. FETα
cells were grown to 80% confluence followed by deprivation of
growth factors in the absence or presence of 5 ng/ml TGFβ for 48 h.
Assessment of apoptotic activity of exogenous TGFβ was
determined (E) Western blot analysis probing for XIAP and survivin,
using actin as a loading control. (F) DNA fragmentation assay. Error
bars represent S.E.
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and/or colonization in the foreign microenvironment of
distant organs (reviewed by Mehlen and Puisieux [4]).
The loss of TGFβ associated tumor suppressor activity
would be expected to shift this balance towards a higher
capacity for cell survival in the FETα-DN cells. To test
the hypothesis that loss of TGFβ tumor suppressor sig-
naling resulted in a higher capacity for cell survival, we
utilized growth factor deprivation as a cell survival stress
model to compare FETα and FETα-DN cells as previ-
ously described for FET cells [16]. Cells were deprived of
growth factors for 48 h followed by determination of
apoptosis. Assessment for apoptotic behavior was per-
formed by immunoblot analysis probing for poly-(ADP-
ribose) polymerase (PARP) expression and cleavage. The
appearance of cleaved products of PARP (88 kDa) has
been widely used as an indicator of apoptosis [45].
Immunoblot analysis was used to probe for PARP fol-
lowing 48 hrs GFDS. Figure 3A illustrates that PARP
cleavage is robust in FETα cells deprived of growth fac-
tors for 48 h while PARP cleavage in FETα-DN cells is
low. Additional confirmation of an enhanced survival
phenotype in FETα-DN cells was obtained by DNA frag-
mentation analysis after 48 hrs GFDS. Figure 3B indi-
cates that FETα cells had a time dependent increase in
DNA fragmentation during GFDS (up to 7-fold at 48 h)
as compared to FETα-DN cells. Taken together, theseresults indicate that endogenous TGFβ signaling is respon-
sible for a high level of apoptotic signaling in FETα cells as
abrogation of TGFβ inhibitory signaling in the FETα-DN
cells rendered the cells more resistant to apoptosis.
Increased AKT activation and survivin/XIAP expression
through repression of TGFβ signaling contributes to cell
survival
Based on our previous observation that endogenous
TGFβ signaling repressed PI3K/AKT signaling in tissue
culture and that this repression was critical to induction
of apoptosis in stressed FET cells [16], we determined
whether PI3K/AKT activation by repression of TGFβ sig-
naling contributed to the enhanced cell survival that
resulted from loss of TGFβ inhibitory signaling in FETα-
Whole Cell Lysate






























Figure 4 Determination of the localization and interaction of
molecular markers in vitro. FETα and FETα-DN cells were grown to
80% confluence followed by growth factor deprivation for 48 h. (A)
Subcellular fractionation to separate cytosolic from mitochondrial
fractions was performed on FETα and FETα-DN cells followed by
western blot analysis probing for XIAP and survivin. Hsp70 and porin
proteins were used as compartmentalization controls for cytosol and
mitochondria, respectively; or (B) Differences in survivin/XIAP
complex formation were determined by immunoprecipitation with
XIAP mouse monoclonal antibody followed by western blot analysis
was performed for survivin.
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PI3K/AKT signaling. Cells were grown to 80% conflu-
ence and deprived of growth factors for 48 h then sub-
jected to immunoblot analysis for AKT phosphorylation.
The results showed that phosphorylation of AKT was
decreased in FETα cells relative to FETα-DN cells under
both GFDS stress and normal growth conditions
(Figure 3C). To confirm that PI3K/AKT signaling was
linked to cell survival in FETα-DN cells we treated cells
with LY294002, a potent inhibitor of PI3K. The effect of
LY294002 inhibition on cell survival was determined by
growing cells to 80% confluence followed by growth
factor deprivation for 48 h in the presence of DMSO or
25 uM LY294002. Confirmation of inhibition of apop-
tosis was assessed by DNA fragmentation analysis.
Results demonstrated that LY294002 treated FETα-DN
cells had a 4 fold increase in apoptosis compared to
DMSO treated cells (Figure 3D).
Survivin has been implicated in aberrant cell survival
exhibited by tumorigenic cells [24]. AKT mediated phos-
phorylation of XIAP within the Bir1 domain has been
shown to reduce ubiquitination of this protein and thus
enhance its stabilization [29]. There is evidence indicat-
ing that XIAP is stabilized through its interaction with
survivin [27]. Survivin protects XIAP from proteasomal
degradation and antagonizes apoptosome-mediated cell
death through the ability of XIAP to inhibit caspase acti-
vation [26]. Consequently, we hypothesized inhibition of
TGFβ signaling would also enhance expression of both
survivin and XIAP. Cells were grown to 80% confluence
then treated with 5 ng/mL TGFβ in combination with
GFDS for 48 h followed by immunoblot analysis for sur-
vivin, XIAP and actin. As shown in Figure 3E, exogenous
TGFβ inhibited survivin and XIAP expression in stressed
FETα cells. To assess the effect of TGFβ treatment on
cell survival, cells were treated in the presence or ab-
sence of 5 ng/mL TGFβ in combination with GFDS for
48 h followed by DNA fragmentation assays which
showed a 3-fold increase in DNA fragmentation of FETα
cells treated with TGFβ (Figure 3F). These results indi-
cate that TGFβ mediated inhibition of survivin and
XIAP expression is associated with FETα cell sensitivity
to apoptosis.
Localization of survivin plays a major role in its
function. Survivin can be nuclear, mitochondrial, cyto-
plasmic or associated with the mitotic apparatus [46].
It has been reported that tumor cells have high levels
of survivin in the mitochondria that are released into
the cytosol upon stress stimulation to provide a cyto-
protective effect [26]. Cytoplasmic survivin binds XIAP
and enhances XIAP stability by protecting it from pro-
teasomal degradation and antagonizes apoptosome-
mediated cell death through the ability of XIAP to in-
hibit caspase activation in vivo [26]. Therefore wehypothesized that abrogation of TGFβ signaling
resulted in enhanced expression of survivin and XIAP
in the cytoplasm. To test this hypothesis we performed
subcellular fractionation to interrogate survivin and
XIAP localization in FETα versus FETα-DN cells
in vitro. The rationale for separation of the cytosolic
and mitochondrial fractions was to assess whether
there were differences in the cytoplasmic pools of sur-
vivin between the cell lines that correlates with the
enhanced cell survival signaling observed in FETα-DN
cells. Porin was used as a mitochondrial specific con-
trol, while Hsp70 was used as a cytosolic compartment
marker. Figure 4A shows that FETα-DN cells have
more cytosolic and mitochondrial survivin and XIAP,
while no difference was observed in nuclear survivin
(data not shown). Immunoprecipitation (IP)/western
blot analysis was performed to confirm that the stabil-
izing complex formation by these two proteins was
more prominent in FETα-DN cells. Figure 4B shows
FETα and FETα-DN lysates subjected to IP for XIAP
followed by immunoblot analysis of survivin, while the
supernatant was probed for actin as an experimental
control. Our results showed that FETα-DN cells have
greater complex formation between XIAP and survivin
proteins under stress conditions than FETα cells.
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marker expression was also reflected in vivo, immuno-
histochemical staining (IHC) using specific antibodies
for pAKT and XIAP was employed to stain tissue sec-
tions of orthotopic implants. IHC staining of FETα
and FETα-DN orthotopic implants was performed
with a phosphospecific AKT S473 antibody. A block-
ing peptide that corresponds to the same epitope as
the antibody was used as a negative control. Not sur-
prisingly, AKT activation was visible in both FETα and
FETα-DN histological slides processed simultaneously.
However, the intensity of staining was more pro-
nounced in the FETα-DN implants (Figure 5A). To
determine whether differences in XIAP expression
were associated with cell survival, IHC staining was
performed on FETα and FETα-DN implants with a
XIAP specific antibody and a specific blocking peptide
control (Figure 5B). Our results showed that FETα-DN
implants had stronger staining for XIAP as compared
to FETα implants. Collectively, these results indicate
that TGFβ signaling leads to repression of activated
AKT and XIAP expression, and their subsequent asso-
















































Figure 5 Determination of the status of molecular markers
in vivo. (A) Immunohistochemical staining of pAKT-S473 performed
on FETα and FETα-DN primary tumors. To confirm antibody
specificity, a blocking peptide was used. (B) Immunohistochemical
staining of XIAP protein performed on FETα and FETα-DN primary
tumors. To confirm antibody specificity, a blocking peptide was
used..Restoration of TGFβ signaling to native cells with
compromised TGFβ signaling suppressed cell survival
and metastasis in vivo
Up to this point demonstration of TGFβ mediated sup-
pression of metastases was based on genetic blockade of
TGFβ signaling. We extended these results by using the
reverse strategy in which metastatic capability in native
colon carcinoma cells was reversed through introduction
of TGFβ receptor Smad signaling. CBS is a human colon
carcinoma cell line that has attenuated TGFβ signaling
as a result of reduced expression of TGFβ receptor type
II [38]. TGFβ sensitivity was restored to native CBS cells
through stable reintroduction of TGFβ type II receptor
(designated CBS-RII). Subcellular fractionation was per-
formed on CBS and CBS-RII cells to determine whether
restoration of TGFβ receptor signaling resulted in sup-
pression of survivin/XIAP expression. CBS-RII cells
exhibited reduced survivin and XIAP expression as com-
pared with CBS cells in vitro (Figure 6). Porin was used
as a mitochondrial specific control, while tubulin was
used as a cytosolic compartment marker. Reintroduction
of Smad-dependent TGFβ signaling resulted in decreased
expression of cytoplasmic survivin and XIAP in CBS-RII
cells.
To determine if reintroduction of TGFβ signaling to
the CBS cells would affect their metastatic capability, we
performed orthotopic implantation experiments. Figure
7A and 7B compares GFP fluorescence of the primary
cancers and liver isolated from animals orthotopically





















Figure 6 Restoration of TGFβ signaling suppresses enhanced
cell survival signaling in vitro. The native CBS cell line (low
expression of TGFβRII receptor) and CBS-RII (transfected with
TGFβRII) were utilized to demonstrate that re-introduction of TGFβ
signaling results in suppression of cell survival signaling. CBS and
CBS-RII cells were grown to 80% confluence, and subjected to GFDS
for 48 h followed by subcellular fractionation to separate cytosolic
from mitochondrial fractions. Western blot analysis was used to
probe XIAP and survivin. Tubulin and porin proteins were used as
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Figure 7 Metastasis is suppressed through reconstitution of
TGFβ signaling. (A) Fluorescent images of primary tumors and the
liver from CBS-RII orthotopically implanted animals. Green
fluorescence reflects metastatic colony formation from the primary
tumor. (B) Fluorescent images of primary tumors and the liver from
CBS orthotopically implanted animals. Green fluorescence reflects
robust metastatic colony formation from the primary tumor. (C-D)
Primary tumors established in animals orthotopically implanted with
CBS-RII and CBS tumors were processed for KI-67 and TUNEL
staining. Both KI-67 and TUNEL images were captured at 200x
magnification. (E-F) Primary tumors formed by CBS-RII and CBS cells
were analyzed to evaluate the proliferation and apoptotic rates.
Image J software was employed to quantify positive staining cells
and total number of cells. Statistical significance was determined
using two tailed student’s t test with p value less than 0.0002.
Simms et al. BMC Cancer 2012, 12:221 Page 10 of 14
http://www.biomedcentral.com/1471-2407/12/221results show that liver from CBS bearing animals had
significantly more metastatic colony formation as reflected
by green fluorescence, while CBS-RII bearing animals had
less. Note that the yellow fluorescence comes from the bil-
iary tree. Table 3 summarizes the results of implantation
with xenografts formed by CBS-RII and CBS cells. The
lungs and liver of each animal were sequentially sectioned
at 1-mm intervals. We observed 100% invasiveness at the
primary tumor site for both cell types. However, distal
metastatic colony formation was notably different between
CBS and CBS-RII animals, in which 2/20 CBS-RII bearing
animals compared to 17/26 CBS bearing animals showed
distal metastases. CBS-RII bearing animals had a 10%
metastatic rate compared to a 65% metastatic rate
observed in CBS bearing animals for equally sized primary
tumors reflected by a robust reduction of the percentage
of animals bearing microscopic metastases using histo-
logical assessment methodology previously described [42].
Ectopic expression of TGFβRII in CBS-RII cells did not
prevent primary invasive tumor formation but did sup-
press the metastatic phenotype. Proliferative potential and
survival signaling were assessed in situ by KI-67 and
TUNEL assays as previously described. Immunohisto-
chemical staining of KI-67 showed that both CBS-RII and
CBS tumors had positive staining for KI-67 antigen. KI-67
staining indicated no differences in the proliferation rates
between CBS-RII and CBS implanted animals (Figure 7D
and 7F). However, TUNEL staining was higher in tumors
from CBS-RII implanted animals thus, reflecting a larger
number of cells undergoing apoptosis in CBS-RII tumors
as compared to CBS tumors (Figure 7C). The apoptotic
rate of CBS-RII implants was 5-fold that of CBS implants
(Figure 7E). Taken together these results indicate that res-
toration of TGFβ receptor/Smad signaling in CBS-RII
cells is not capable of suppressing tumor initiation and in-
vasion, but does suppress the progression of a primary in-
vasive carcinoma to a robust metastatic capability.
Discussion
TGFβ primes breast cancer cells for metastasis to the
lung through effects on cells in the lung microenviron-
ment [47]. Similarly, TGFβ interacts with the bone
microenvironment to enhance breast cancer metastasis
[47,48]. Our results show a novel role for TGFβ signal-
ing in human colon carcinoma, as a direct metastatic
suppressor through inhibition of cell survival despite ac-











(65%)primary cancer cells with low metastatic potential. The
mechanism of this pro-apoptotic effect appears to in-
volve inhibition of XIAP mediated cell survival
mechanisms. FETα cells have aberrant EGFR activa-
tion via TGFα over-expression resulting in formation
of invasive primary colon cancer (Figure 1A), but have
poor potential for forming distal organ metastasis, due
to sensitivity to their intrinsic apoptotic TGFβ signal-
ing, as shown by high levels of metastatic colonies
when TGFβ signaling was blocked in FETα-DN cells
(Figure 1B). We have shown that primary tumor for-
mation is linked to enhanced cell survival mechanisms
exhibited by these cells [33]. The importance of cell
survival is further emphasized by the observation that
abrogation of TGFβ signaling in the FETα-DN cells
does not affect invasion at the primary site but facili-
tates secondary site colonization.
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mechanisms that must be acquired by tumor cells before
they obtain a robust metastatic capability. Two import-
ant rate limiting steps to metastasis are invasion and dis-
tal colony formation. There are few in vivo model
systems that enable the study of both invasion and distal
colony formation. We have utilized an orthotopic im-
plantation model of colon cancer to allow observation of
these events. The orthotopic implantation model allows
for assessment of the progression of colon cancer evi-
dent by invasion at the primary tumor site and distal
colonization to the liver and lungs. These sites of metas-
tasis recapitulate the natural progression of human dis-
ease. Our results show that both FETα and FETα-DN
cells were able to invade the bowel wall and the normal
colon crypts to form a carcinoma. However, the orthoto-
pic implants showed that the FETα-DN cells with abro-
gated TGFβ signaling were able to effectively generate
colonies despite the stress of growth in the foreign
microenvironment of distal organs, emphasizing the role
of TGFβ as a metastasis suppressor as well as a tumor
suppressor.
The reconstitution of TGFβ receptor signaling in CBS-
RII cells resulted in decreased metastases indicating the
potential for treatment of metastasis through enhanced
TGFβ receptor mediated signaling. The balance between
oncogenes and tumor suppressor activities is a necessity
for normal functioning cells and tissues; however, when
the balance shifts towards oncogenicity it results in
tumorigenesis and malignant progression. CBS cells have
been shown to be similar to the FETα engineered cells
in that they have constitutive EGFR activation in
addition to the attenuation of TGFβ tumor suppressor
activity [38,49], thus providing a mechanism for reten-
tion of the capability of forming an invasive cancer at
the primary site despite TGFβ activity generated by ec-
topic expression of the TGFβRII.
Activation of inappropriate survival mechanisms such
as survivin/XIAP and/or inactivation of tumor suppres-
sors (i.e., TGFβ) are involved in promoting cell survival
during tumorigenicity and metastasis. The ability of ma-
lignant cells to withstand environmental stress is consid-
ered an important factor in tumor development and
progression [1] as well as in the metastatic process [4].
Loss of TGFβ-mediated apoptosis may contribute to
tumor progression and metastasis under such stress con-
ditions. Mehlen and Puisieux [4] and Giampieri et al.,
[50] have reviewed the particular importance of aberrant
cell survival in the establishment of metastatic colonies
in the foreign microenvironment of organs distal to the
primary tumor site. Moreover, different stages of the
metastatic process show different mechanisms for aber-
rant survival. We have shown that abrogation of auto-
crine TGFβ enables increased PI3K/AKT activation inFETα-DN cells under GFDS, which shifts the balance of
signaling during stress by these cells from apoptosis to
survival thus contributing to resistance to stress induced
apoptosis.
The significance of survivin subcellular localization in
cell survival has been addressed by the Altieri laboratory
[46]. Nuclear survivin is associated with proliferation
while cytoplasmic survivin is associated with cell survival
[51]. Survivin associates with another IAP family mem-
ber, XIAP, in response to cell death stimuli [27]. The re-
sultant survivin-XIAP complex promotes increased
XIAP stability from ubiquitination and subsequent pro-
teosomal degradation [26]. Tumor cells have high pools
of survivin present between the mitochondrial mem-
branes that are released into the cytosol upon stress
stimulation [28]. It was shown that when cytoplasmic
survivin is not phosphorylated at S20 it binds XIAP and
enhances XIAP stability by protecting it from proteaso-
mal degradation thus enabling antagonization of
apoptosome-mediated cell death through the ability of
XIAP to inhibit caspase −3, -7 and −9 activation in vivo
[26]. A recent study has documented that nuclear survi-
vin has reduced stability and is not cytoprotective [52].
Our study shows for the first time that abrogation of
TGFβ signaling results in enhanced cytosolic localization
of survivin and XIAP proteins which are associated with
enhanced cell survival capability and eventual metastasis
in the FET colon cancer cell model (Figure 4A). This ob-
servation was further validated by restoring TGFβ sensi-
tivity in the native CBS colon carcinoma cell line
(Figure 6).
We have utilized genetic modification of TGFβ recep-
tors to show that TGFβ receptor mediated signaling is
critical to the suppression of metastasis in the FET and
CBS colon cancer models. The question arises as to the
potential breadth of cancers in which TGFβ receptor
modulation would be a factor and whether pharmaco-
logical modulation would be possible. Over the past
15 years we and others have shown that transcriptional
repression of either RI or RII is seen in a variety of histo-
logical types of cancer including colon, breast, lung and
pancreatic cells lines [7-9,53-56]. Along this line, several
clinical studies have indicated that cancer progression is
associated with loss of TGFβ receptors in types of can-
cers where TGFβ mutation is rare or in the case of colon
cancer, in patient samples without microsatellite instabil-
ity thereby implying a lack of mutation [57-62]. More re-
cently, we have shown that cancer cell lines with TGFβ
receptor repression due to histone acetylation can be
rescued by treatment with a clinical HDAC inhibitor
candidate. Importantly, this pharmacological rescue
results in TGFβ signaling dependent induction of apop-
tosis through disruption of survivin/XIAP mediated cell
survival as seen both in vitro and in vivo in the 2 cell
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and 3 breast cancer cell lines [63]. Consequently, based
on the broad range of cell lines showing TGFβ receptor
repression, the clinical studies of cancer progression
related to TGFβ receptor loss in cancers that rarely show
TGFβ receptor mutations and the pharmacological
responses of cell lines demonstrating TGFβ receptor
transcriptional repression, the subset of cancers in which
TGFβ receptor signaling potentially enables metastasis
appears to be significant in a subset of cancers. More-
over, the mechanism of TGFβ receptor repression may
be susceptible to pharmacological intervention [63].
This dichotomous role of TGFβ signaling with respect
to tumor progression is problematic for strategies to tar-
get aberrant TGFβ signaling in cancer. The observations
presented here raise the concern that abrogation of
TGFβ signaling may lead to acceleration of malignant
progression even in the biological context of invasive
cancer. However, reconstitution of deficient TGFβ sig-
naling can result in the direct activation of cell death
and inhibition of metastasis thus indicating TGFβ is a
metastatic suppressor in fully invasive carcinomas, thus
indicating that at least in some cancer contexts the con-
cept of enhancing TGFβ activity and/or the mechanisms
by which TGFβ generates cell death could be of thera-
peutic value in highly progressed cancers.
Conclusion
The observations presented here indicate a metastasis
suppressor role for TGFβ signaling in human colon can-
cer cells. This raises the concern that therapies targeting
inhibition of TGFβ signaling may be imprudent in some
patient populations with residual TGFβ tumor suppres-
sor activity where consideration of enhancement of TGFβ
signaling may be beneficial.
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